home        About us        About Viva
About Viva

The Place for Structure-based Drug Discovery

Based in Shanghai, China Viva Biotech is one of the few biology-focused CROs providing preclinical drug discovery research services.

Viva is privately owned and financed by leading investors in the US. It currently employs close to 200 scientists at a 65,000 sq. ft. research center. The center is equipped with state-of-the-art instruments housed by modern laboratories in an artistically designed building. Viva now works with all of the top ten largest global pharmaceutical companies and dozens of small to medium sized US and Europe-based businesses in studies of gene-to-structure, in vitro and in vivo assays, target ID, ADME, animal models, and more.

Dating back to 2006, Viva’s team has been known for pioneering structural biology services. Viva’s experience, track record, and number of project teams focused in protein science are unmatched by any other company in China. By building on this strength, Viva is determined to increase the existing service model, build additional project teams with the same scientific rigor and quality, and expand into other challenging disciplines that play key roles in drug discovery research. Viva is keen on improving its technology and expertise while distinguishing itself from large chemistry-focused CROs.

Viva is designed with a setup similar to a pharmaceutical company to better serve the pharmaceutical industry. To ensure that there are no conflicts of interest, Viva is not proactively pursuing drug discovery on its own but rather works hard to protect their client’s IP with all the necessary procedures and mandates in place.

Currently, in vivo models set up at Viva are focused on disease areas such as oncology, diabetes, and pain. We are actively seeking stand-alone projects and welcome partnerships with any company which is interested in preclinical drug discover. Our current business models are illustrated below:

               Business model I - Fee for Service:

               FTE based of Milestone based

Business model II

Milestone-based Partnership: